Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab + Chemotherapy in STK11-mutated NSCLC
NCT06331650Phase 2
Key facts
- Status
- Recruiting
- Start
- Aug 2023
- Primary completion
- Aug 2025
- Countries
- 1
- Sponsor
- Guangzhou Institute of Respiratory Health
- Modality
- Bispecific Antibodies
- Drugs
- cadonilimab
- Conditions
- non-small cell lung cancer (NSCLC)
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab in non-small cell lung cancer (NSCLC), sponsored by Guangzhou Institute of Respiratory Health. Primary endpoints: Safety and tolerability at 2 years and Objective Response Rate at 2 years. Started Aug 2023; status: recruiting.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
Cadonilimab + Chemotherapy
Cadonilimab combined with standard chemotherapy
03
Who it enrols
Patients with histologically confirmed advanced or recurrent NSCLC with STK11 mutations and no other actionable driver mutations (EGFR, ALK, etc.). Must be treatment-naive for advanced disease (first-line).
04
Endpoints
Primary
Safety and tolerability
Objective Response Rate
Beyond the preview
Go deeper on NCT06331650.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06331650.